Moxibustion for alleviating chemotherapy-induced gastrointestinal adverse effects: A systematic review of randomized controlled trials.

Objective: This systematic review aims to assess whether moxibustion is effective and safe for gastrointestinal adverse effects, a common and thorny issue arising from chemotherapy.

Methods: Seven electronic databases were searched up to August 28, 2021, to identify randomized controlled trials (RCTs) comparing moxibustion versus non-moxibustion treatments for various gastrointestinal adverse effects after chemotherapy. The Karnofsky performance status (KPS) and quality of life scores and the incidence of moxibustion-related adverse events were also investigated.

Shensu IV prevents glomerular podocyte injury in nephrotic rats via promoting lncRNA H19/DIRAS3-mediated autophagy.

Shensu IV is a Chinese prescription well-known for its function in treating chronic kidney diseases. However, the potential mechanisms underlying how Shensu IV exerts its effects remain unclear. In the present study, we investigated the effects of Shensu IV on glomerular podocyte injury in nephrotic rats and puromycin-induced injury in cultured podocytes, and assessed the associated molecular mechanisms.

Acute kidney injury after a stroke: A PRISMA-compliant meta-analysis.

Background: The relationship between acute kidney injury (AKI) and stroke needs quantitative summary. Therefore, we analyzed the associations between AKI and stroke including the incidence, risk factors of AKI after stroke, and the influence of AKI after a stroke on prognosis of stroke.

Methods: Articles published until November 2019 were searched based on the following databases: PubMed, Web of Science, EMBASE, Medline, and Google Scholar.